Pietro Rigoni

Pietro Rigoni

Auto-generated profile, based on publicly available information

Pietro Rigoni

Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Woman’s and Child Health Department, University of Padova, Padova 35128, Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
RMRita Milazzo
Rita Milazzo
AMAnnita Montepeloso
Annita Montepeloso
RKRajesh Kumar
Rajesh Kumar
FFFrancesca Ferro
Francesca Ferro
ECEleonora Cavalca
Eleonora Cavalca
ABAlessandra Biffi
Alessandra Biffi
The conditions supporting the generation of microglia-like cells in the central nervous system (CNS) after transplantation of hematopoietic stem/progenitor cells (HSPC) have been studied to advance the treatment of neurodegenerative disorders. Here, we explored the transplantation efficacy of different cell subsets and delivery routes with the goal of favoring the establishment of a stable and exclusive engraftment of HSPCs and their progeny in the CNS of female mice. In this setting, we show that the CNS environment drives the expansion, distribution and myeloid differentiation of the locally transplanted cells towards a microglia-like phenotype. Intra-CNS transplantation of HSPCs engineered to overexpress TREM2 decreased neuroinflammation, Aβ aggregation and improved memory in 5xFAD female mice. Our proof of concept study demonstrates the therapeutic potential of HSPC gene therapy for Alzheimer’s disease.

7 January 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
YCYuri Ciervo
Yuri Ciervo
PRPietro Rigoni
Pietro Rigoni
LBLinda Bucciarelli
Linda Bucciarelli
MLMartina Lombi
Martina Lombi
FPFederico Pratesi
Federico Pratesi
ABAlessandra Biffi
Alessandra Biffi
Autologous hematopoietic stem/progenitor cell (HSC)–gene therapy (GT) represents a promising therapeutic option for progranulin (PGRN)–related neurodegenerative diseases due to mutations in the PGRN encoding gene ( GRN ), such as frontotemporal dementia (FTD) and neuronal ceroid lipofuscinosis 11 (CLN11). These conditions are characterized by a deficiency in PGRN, have no cure, and represent an unmet medical need. We report on the efficacy and feasibility of an HSC GT approach that used a lentiviral vector encoding the human GRN complementary DNA to transduce HSCs that then were transplanted into a Grn −/− mouse model, which mirrors both FTD and CLN11 phenotypes. Two promoters, one with medium-low strength ( HLA-DRA gene–based promoter regulated by inflammation) and the other with medium-high strength [ubiquitous phosphoglycerate kinase (PGK) promoter], were compared for HSC transduction. Moreover, intravenous and intracerebroventricular HSC administration were compared. Under all tested conditions, a partial reconstitution of PGRN production by microglia-like cells (MLCs) derived from genetically corrected Grn −/− HSCs was observed, which uniformly led to a correction of lipid accumulation, reduced gliosis, and improved social recognition in Grn −/− mice. Therapeutic effects were similarly achieved with either of the promoters and administration routes and particularly also when the PGRN-expressing cells and their MLC progeny had engrafted exclusively in the central nervous system (CNS) after intracerebroventricular transplantation. These findings suggest that a durable yet modest restoration of PGRN expression in the CNS is sufficient to correct pathology.